GREAT BASIN SCIENTIFIC, INC. (NASDAQ:GBSN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) Compensatory Arrangements of Certain Officers
On September 18, 2017, Great Basin Scientific, Inc. (the “Company”) and Mr. Rona agreed to amend his employment agreement such that Mr. Rona will devote approximately 20 hours a week to the Company at a revised salary of $104,000.
Item 9.01Financial Statements and Exhibits.
*Filed herewith.
Great Basin Scientific, Inc. ExhibitEX-10.1 2 gbsn-ex101_45.htm EX-10.1 gbsn-ex101_45.htm Exhibit 10.1 September 22,…To view the full exhibit click here
About GREAT BASIN SCIENTIFIC, INC. (NASDAQ:GBSN)
Great Basin Scientific, Inc. is a molecular diagnostic testing company. The Company is focused on the development and commercialization of its molecular diagnostic platform designed to test for infectious diseases, especially hospital-acquired infections. Its commercially available tests are clostridium difficile (C. diff) and Group B Strep. Its system includes an analyzer and a diagnostic cartridge. Each analyzer contains a module into, which individual test cartridges are placed. Its other diagnostic assays in the late stages of product development include a pre-surgical nasal screen for Staphylococcus aureus (SA), food borne pathogen panel, panel for candida blood infections, test for pertussis and a test for Chlamydia tracomatis (CT)/Neisseria gonorrhea (NG). The Company also has a pipeline of assays in an early stage of development, including respiratory testing and sepsis (blood infection) panels. It markets a platform of molecular testing in small to medium sized hospitals.
